IL2RA and cancer: Notably, a recent effort to exploit CD25-biased IL-2 signaling in cancer immunotherapy involved the development of an IL-2/CD25 FP, which forms inactive head-to-tail transdimers that slowly dissociate into monomeric, biologically active units.36